导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.87% | 374/4773 |
| 近一周 | -2.63% | 2726/5462 |
| 近一月 | -7.37% | 3800/5421 |
| 近一季 | -13.81% | 4082/5209 |
| 近半年 | 13.89% | 336/4920 |
| 近一年 | 23.93% | 303/4366 |
| 近两年 | 139.88% | 261/2954 |
| 近三年 | 109.29% | 112/2253 |
| 成立以来 | 96.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.98% 2979/4961 |
58.47% 424/5312 |
- - |
- - |
| 2025 | 54.43% 356/4813 |
-1.49% 2678/3635 |
2.78% 1358/4076 |
50.92% 287/4524 |
1.07% 1556/4813 |
| 2024 | 18.77% 577/3463 |
-1.60% 1246/2808 |
1.68% 456/3014 |
14.05% 2053/3129 |
4.08% 737/3463 |
| 2023 | 0.75% 392/2656 |
19.50% 142/2280 |
-1.17% 448/2385 |
-11.63% 2082/2515 |
-3.46% 693/2655 |
| 2022 | -30.55% 1636/2207 |
-23.37% 1730/1919 |
3.05% 1223/2016 |
-15.18% 1237/2113 |
3.68% 657/2208 |
| 2021 | 8.89% 467/1822 |
-6.01% 971/1255 |
15.28% 232/1330 |
-8.29% 1122/1466 |
9.58% 118/1822 |
| 2020 | 36.41% 396/1250 |
-2.95% 281/1028 |
27.27% 131/1067 |
3.09% 995/1164 |
7.13% 726/1184 |
| 2019 | 57.47% 62/1092 |
41.20% 40/739 |
-10.47% 740/788 |
12.58% 32/850 |
10.65% 108/918 |
| 2018 | -39.77% 613/834 |
- - |
-17.74% 584/631 |
-13.30% 635/660 |
-14.57% 590/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 招商深证TMT50ETF联接C VS. 长安沪深300非周期A(740101) |